Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT3 | O60678 | 8/20 | 0.52 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.47 |
| ▸ | IMPDH2 | P12268 | 4/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.41 |
| ▸ | HPGDS | O60760 | 1/20 | 0.41 |
| ▸ | CKS1B | P61024 | 1/20 | 0.41 |
| ▸ | SKP1 | P63208 | 1/20 | 0.41 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | CSF1R | P07333 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31206126 | 0.85 | KDM1A (0.51) | KDM1AMAOBCKS1BSKP1SKP2 | |
| SCHEMBL31206091 | 0.83 | KDM1A (0.44) | KDM1AMAOBCKS1BSKP1SKP2 | |
| SCHEMBL29862471 | 0.83 | ALDH1A1 (0.62) | SYK | |
| SCHEMBL3313868 | 0.83 | ALDH1A1 (0.62) | SYK | |
| SCHEMBL31206061 | 0.80 | NAMPT (0.52) | KDM1AMAOBCKS1BSKP1SKP2 | |
| SCHEMBL567640 | 0.79 | NAMPT (0.51) | CKS1BSKP1SKP2 | |
| SCHEMBL5407173 | 0.79 | ROCK2 (0.58) | SYK | |
| SCHEMBL10135596 | 0.78 | MCHR1 (0.50) | — | |
| Trifluoroacetic Acid SCHEMBL3318885 | 0.78 | ALDH1A1 (0.56) | SYK | |
| SCHEMBL23453276 | 0.77 | IMPDH2 (0.50) | PRMT3IMPDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2125744-B1 | CYCLOALKYLAMINE SUBSTITUTED ISOQUINOLONE AND ISOQUINOLINONE DERIVATIVES | SANOFI AVENTIS (FR) | 2011-04-13 | — | — | EP | disclosed |
| EP-2125744-B1 | CYCLOALKYLAMINE SUBSTITUTED ISOQUINOLONE AND ISOQUINOLINONE DERIVATIVES | SANOFI AVENTIS (FR) | 2011-04-13 | — | — | EP | disclosed |
| US-20100056568-A1 | Cycloalkylamine substituted isoquinolone and isoquinolinone derivatives | SANOFI-AVENTIS (FR) | 2010-03-04 | — | — | US | disclosed |
| US-20100056568-A1 | Cycloalkylamine substituted isoquinolone and isoquinolinone derivatives | SANOFI-AVENTIS (FR) | 2010-03-04 | — | — | US | disclosed |
| US-20100056568-A1 | Cycloalkylamine substituted isoquinolone and isoquinolinone derivatives | SANOFI-AVENTIS (FR) | 2010-03-04 | — | — | US | disclosed |
| EP-2125744-A1 | CYCLOALKYLAMINE SUBSTITUTED ISOQUINOLONE AND ISOQUINOLINONE DERIVATIVES | Sanofi-Aventis (FR) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008077553-A1 | CYCLOALKYLAMINE SUBSTITUTED ISOQUINOLONE AND ISOQUINOLINONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056568-A1 | Cycloalkylamine substituted isoquinolone and isoquinolinone derivatives | MYLK2, MYLK, MYLK3 | PRMT3 917/4885SMYD3 2923/4885IMPDH2 797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.